Experimental allergic encephalomyelitis (EAE) is an autoimmune disease of the central nervous system that can be transferred to naive mice via CD4 + T cells isolated from appropriately immunized mice. We have evaluated the effects of recombinant murine interleukin 12 (rmi1:12), a potent inducer of interferon 3/(IFN-3') and promoter ofThl T cell development, on the course of adoptively transferred EAE. The transfer of lymph node cells (LNC) isolated from proteolipid protein (PLP)-primed animals and stimulated in vitro with PLP to naive mice resulted in a progressive paralytic disease culminating in complete hind limb paralysis in the majority of the recipients. When mice were injected with LNC that had been stimulated in vitro with PLP in the presence of rmi1:12, the subsequent course of disease was more severe and prolonged. The addition of rmlL-12 during the in vitro stimulation with PLP resulted in a 10-fold increase in IFN-'y and a 2-fold increase in tumor necrosis factor (TNF) ct in the supernatants, relative to LNC stimulated with PLP alone. However, neutralization of IFN-3, or TNF-c~ in vitro with specific antibodies did not abrogate the ability of rmlL-12 to exacerbate the subsequent disease. Similarly, mice treated with rmi1:12 in vivo after the transfer of antigen-stimulated LNC developed a more severe and prolonged course of disease compared with vehicle-treated control animals. In contrast, treatment of mice with an antibody to murine I1:12 after cell transfer completely prevented paralysis, with only 40% of the mice developing mild disease. These results demonstrate that in vitro stimulation of antigen primed LNC with PLP and rmlb12 enhances their subsequent encephalitogenicity. Furthermore, inhibition of endogenous IL-12 in vivo after LNC transfer prevented paralysis, suggesting that endogenous 11:12 plays a pivotal role in the pathogenesis of this model of autoimmune disease.
E
xperimental allergic encephalomyelitis (EAE) is a T cellr mediated autoimmune disease of the central nervous system (CNS). Disease can be induced in susceptible strains of mice by immunization with CNS myelin antigens or, alternatively, disease can be passively transferred to susceptible mice via antigen-stimulated CD4 + T cells (1) . Elimination of CD4 + cells, but not CD8 + cells, prevents disease transfer, thus confirming the role of CD4 + T cells in disease induction. The clinical course of disease is characterized by weight loss and hind limb weakness, which commonly progresses to bilateral hind limb paralysis. In most species, the disease remits spontaneously, with the sequence of recovery being the reverse of that of onset. Acute disease is associated with the infiltration of CD4 + tymphocytes followed by the recruitment of monocytes and macrophages into the CNS lesions (2) . Analysis of cytokine profiles in the CNS by mRNA expression after the transfer of myelin basic protein (MBP)-stimulated lymph node cells (LNC) demonstrated that the onset of disease is associated with cytokine expression typical of a Thl-type immune response, with high levels of I1.2 and IFN-'y mRNA (3) . In contrast, immunohistochemical anal->'sis demonstrated that II_.4, a cytokine produced by Th2 cells, appeared transiently later in the course of disease as symptoms began to resolve (2) . Recovery from disease is also associated with a decline in Ib2 and IFN-3~ mRNA and a concomitant rise in Ibl0 mRNA consistent with a Th2-type response (3) . These changes in cytokine profiles suggest that the onset of disease and subsequent spontaneous recovery are associated with a switch from a predominantly Thl type response to a more typical Th2-type response within the inflammatory loci.
The differentiation pathway that leads to the generation of CD4 + Thl and Th2 cells is regulated at least in part by cytokines released from lymphocytes and accessory cells, with IFN-3{ and I1:4 inducing differentiation to Thl and Th2 cells, respectively (4) (5) (6) . In addition to Ib4 and IFN-% Ibl0 and Ib12 appear to play primary roles in the differentiation of CD4 + T helper cells (7, 8) . Ib12 is a novel heterodimeric cytokine that enhances NK-mediated cytotoxicity and induces IFN-3~ production by NK cells and T lymphocytes (9, 10) . The ability of Ib12 to induce IFN-3'-and promote Thl-specific immune responses has been demonstrated both in vitro (11) and in vivo (12, 13) . In the latter case, administration of IL-12 following Leishmania major infection rendered susceptible BALB/c mice, which normally respond to L. major with preferential expansion of II_,4-and Ibl0--producing Th2 cells, resistant to leishmaniasis. Examination of LNC from these Ibl2-cured mice showed induction of Thl T ceils that produced high levels of .
Given the association between the onset of EAE and a Thl effector T cell population, we evaluated the role of recombinant murine (rm) IL-12 on the course of adoptively transferred EAE using LNC stimulated with a synthetic peptide of myelin proteolipid protein (PLP) in SJL/J mice. Here we report that IL-12 is a key regulator of immune responsiveness in this model of autoimmune disease.
Materials and Methods
Adoptive Transfer of PLP-sensitized LNC. Female SJL/J mice (7-10 wk) were purchased from The Jackson Laboratory (Bar Harbor, ME), housed five to a cage, and fed standard rodent chow diet with water ad libitum. Mice were immunized in two sites on the flank with 75/xg (150 #g total) of mouse PLP peptide comprising residues 139-151 (provided by G. Brown, Genetics Institute). PLP was administered in 200 #1 of CFA containing 2 mg/ml Mycobacterium tuberculosis H37KA (Difco Laboratories, Detroit, MI).
On the day of immunization, mice were injected intravenously with 0.75 x 101~ Bordetella pertussis bacilli (Massachusetts Public Health Laboratories, Boston, MA). 10 d after immunization, lymph nodes (popliteal, axiUary, and brachial) were harvested and the cells resuspended in RPMI-1640 containing 10% fetal bovine serum (Hyclone Laboratories, Inc., Logan, UT), 5 x 10 -s M 2-ME, 100 #g/ml streptomycin, and 100 U/ml penicillin. PLP was added to the cultures at 2 #g/ml. After incubation for 96 h, the cells were harvested, washed twice, and 30 x 10' cells LNC were injected intraperitoneally into naive SJL/J mice. In Vitro Administration of rralbl2 Before Cell Transfer. Recombinant murine IIA2 (20 ng/ml) (Genetics Institute) was added during the in vitro stimulation of LNC with PLP before cell transfer. After 96 h the cells were washed twice, and 30 x 10' cells were transferred to naive SJL/J mice, which were monitored for signs of disease. In separate experiments, LNC were cultured with either antigen alone, antigen plus rmlL12 (20 rig/m1), or antigen plus trolL-12 plus either a neutralizing antibody to IFN-7 (5 #g/m1) (Endogen, Inc., Boston, MA) or 200/~1 of a polydonal rabbit anti-mouse TNF-c~ antibody (Genzyme Corp., Cambridge, MA). At the end of the culture period, supematants were collected (pooled from three flasks) and IFN-7 and TNF-~ measured by ELISA (Genzyme Corp.). 30 x 106 cells from each culture condition were transferred to naive mice, which were monitored for signs of disease. 
ClinicalEvaluation of Diseas~

Resuhs
The Addition of rmlL12 During the In Vitro Stimulation of LNC with PLP Exacerbates Clinical Signs of EAE After Cell
Transfer. LNC from PLP-immunized mice were stimulated in vitro with either PLP alone or PLP and rmIL-12 (20 ng/ml) for 96 h, after which time they were tested for their ability to transfer disease to naive SJL/J mice. Control mice that received LNC stimulated in vitro with PLP developed dinical signs of disease between days 6 and 8. All seven control mice reached scores >~2, with four out of seven mice progressing to complete hind limb paralysis, which lasted between 1 and 4 d (Fig. 1 ). All the control mice recovered by day 19. In contrast, mice that received LNC cultured in vitro with PLP and rmIb12 developed severe EAE with rapid onset of clinical signs ( Fig. 1 ). By day 6, four out seven mice had clinical scores of >12, and all mice developed complete hind limb paralysis by day 8. In this particular experiment, five out of seven mice failed to recover from the paralysis.
To determine the effects of rmIb12 on cytokine production during the in vitro stimulation with antigen, LNC from PLP-primed mice were cultured with either PLP alone or PLP and rmIb12 (20 ng/ml). After 96 h in culture, IFN-7 and TNF-c~ in the supernatant were measured by ELISA. The addition of rmlL-12 during the in vitro stimulation of LNC with PLP resulted in a >10-fold increase in IFN-7 and a 2-fold increase in TNF-oz compared with cells cultured with PLP alone (Table 1) . To determine if stimulation of either IFN-7 or TNF-cx was an essential component of the in vitro effects of rmlb12 on T cell encephalitogenicity, LNC were stimulated with PLP and rmlb12 in the presence of neutralizing antibodies to IFN-'y or TNF-o~. The addition of the neutralizing antibody to IFN-'y during stimulation with PLP and rmlb12 completely neutralized assayable IFN-v but had no effect on the increase in TNF-ot in the supernatants (Table  1) . Similarly, neutralization of TNF-c~ during stimulation with PLP and rmlb12 had no effect on the increase in IFN-'y (Table 1) . Furthermore, cells stimulated in vitro with PLP and rmlD12 in the presence of neutralizing antibodies to either IFN-'y or TNF-c~ still induced severe disease in naive mice with the same kinetics and duration as that seen after the transfer of cells stimulated with PLP and rmlL-12 alone ( Table 1) . The onset of disease in the saline treated control mice ranged between days 6 and 8 after cell transfer, and 80% of the mice progressed to full bilateral hind limb paralysis. Peak disease in the control mice lasted •3 d, after which time the mice spontaneously recovered (Fig. 2) . In contrast, although the onset of clinical signs in mice treated with rmlI:12 was only slightly earlier (day 5), the subsequent progression to peak disease was accelerated, and all mice displayed full hind limb paralysis by day 8. The duration of paralysis was also significantly extended, lasting up to 14 d (range, [11] [12] [13] [14] .
The Effect of In
The Effects of Anti-II.,12 Antibody Administration on the Course of Disease. To determine if endogenous Ib12 is required for the successful transfer of disease, mice were treated with 200 #g of a sheep polyclonal antibody to murine Ib12 every other day for either 6 or 12 d after cell transfer. Control mice received an equal amount of sheep IgG. The onset of clinical signs in the sheep IgG-treated control mice was similar to that seen in untreated mice that received PLP-stimulated LNC (day 6-7, Fig. 3 a) . All control mice developed signs of disease graded I>2 (70% developed full hind limb paralysis). Administration of anti-Ib12 antibody during the first 6 d after cell transfer delayed the onset of clinical signs by '~7 d, but had no effect on the ultimate severity of disease, with all mice reaching a score of >t2 (80% developed full hind limb paralysis). To determine if this delay of disease after cell transfer could be sustained by prolonged administration of anti-Ib12 antibody, mice were treated every other day for 12 d after transfer of PLP primed LNC. This extended treatment with anti-IL-12 antibody not only delayed the onset of disease, but also dramatically reduced the severity of disease, with no mice developing hind limb paralysis and only two out of five mice developing mild signs of disease (Fig. 3 b) . 
Discussion
In this study, we examined the effects of rmlL-12 administration on the development of adoptively transferred EAE after stimulation of LNC with a synthetic peptide corresponding to mouse myelin PLP residues 139-151. This peptide has been used previously for the active induction of EAE in SJL/J mice (14) . Using LNC isolated from PLP-immunized mice, the addition of rmlL-12 during the in vitro stimulation with antigen exacerbated the subsequent clinical signs of disease after cell transfer. A similar effect on disease severity was seen when spleen cells were used to transfer disease (data not shown). These results suggest that in vitro stimulation with rmlL-12 had direct effects on T cell effector function and/or number, ultimately rendering these cells more encephalitogenic.
Previous studies have demonstrated that MBP-specific CD4 § T cells secreting cytokines associated with a Thl phenotype effectively transferred EAE (15) . Consistent with this finding, we observed increases in both IFN-3~ and TNF-c~ in the supernatant of LNC cultures after stimulation in vitro with PLP and rmlb12 compared with cells cultured with antigen alone. Since the production of these secondary cytokines after stimulation with rmlb12 could have effects on accessory cells, we added neutralizing antibodies against IFN-y or TNF-ot to our in vitro cultures. The observation that neutralization of these cytokines did not affect the ability of rmlb12 to exacerbate disease after cell transfer supports the conclusion that rmlL-12 has a direct effect on T cell effector function and/or number and argues against secondary effects mediated by IFN-3/or TNF-o~ during the in vitro stimulation with PLP, In addition, these antibody blocking experiments indicate that, in this setting, the stimulation of either IFN-3' or TNF-c~ by rmlb12 is independent of the production of the other. Although the data strongly suggest a direct effect of rmlL-12 during the in vitro stimulation with PLP, this cannot be unequivocally stated, as it is possible that some bioactive cytokine is present in the cultures despite the absence of detectable levels of IFN-3' and TNF-ot by ELISA.
Although there was a marked increase in both IFN-3, and TNF-ot production in cultures treated with rmlL-12, it is not clear if this reflects the preferential expansion of Thl effector cells, or, alternatively, results from an increase in the production of these cytokines on a per cell basis. To address the effects of rmlb12 on the in vitro responsiveness to PLP, proliferation was measured by [3H]thymidine incorporation of LNC after PLP stimulation. We were unable to demonstrate a difference in antigen-stimulated proliferation in the presence of rmlL-12 when PLP was added at the concentration used to transfer disease (2/~g/ml). There was, however, an enhanced proliferative response at low concentrations of PLP (0.01 /zg/ml) in the presence of rmlL-12 (data not shown), suggesting that rmlL-12 could enhance the expansion of PLPresponsive T cells in vitro. The observation that rmlL-12 did not enhance proliferation at higher doses of antigen may be due to increased production of other cytokines in these cultures, particularly IL-2, which could mask the effects ofrmlbl2 on a subset of T cells.
A profound effect on the course of EAE was also seen when rmlL-12 was administered in vivo after the transfer of PLPstimulated LNC. This in vivo treatment with rmlL-12 accelerated the progression to complete hind limb paralysis and resulted in a severe and prolonged clinical course of disease. Histological and immunohistochemical evaluation of the inflammatory loci of mice killed at peak disease confirmed the presence of multiple perivascular lesions typical of the clinical pathology associated with EAE (data not shown). Although there were no dramatic differences between rmlb 12-treated and control mice in either the cellular composition of the lesions or in the relative extent of IFN-3/staining, preliminary results suggest an increase in the number of inflammatory lesions in rmll.-12-treated mice, which could account for the enhanced disease severity (Waldburger, K., unpublished observation). An extensive histological analysis to determine the nature of the inflammatory response during the course of EAE after rrnlL-12 administration is being conducted.
The in vivo effects of rmll-12 on disease severity are also independent of secondary IFN-3' stimulation, as the combination of rmlb12 and a neutralizing anti-IFN-3, antibody in vivo after cell transfer resulted in a rapid progression of disease, which proved lethal in all mice (Leonard, J. P., K. E. Waldburger, and S. J. Goldman, unpublished observations). Taken together with the observation by us and others that treatment with a neutralizing anti-IFN-3, antibody alone exacerbates disease (16) , these data suggest that rmlIA2 directly activates encephalitogenic T cells in vivo, although we cannot exclude the contribution of secondary effects mediated by TNF-cr
The most compelling evidence for an immunoregulatory role of II.-12 in the pathogenesis of EAE came from experiments in which endogenous IL-12 was blocked after the transfer of PLP-stimulated LNC. In these studies, treatment of mice with anti-IL-12 antibody during the first 6 d after cell transfer significantly delayed the onset of clinical signs; however, the ultimate severity and duration of disease was not affected. In contrast, extending the period of antibody treatment to 12 d completely prevented the development of hind limb paralysis. These data suggest that endogenous 1I.-12 is essential for the effective transfer of disease and demonstrate that prolonged inhibition of endogenous I1.-12 can prevent paral-),sis and substantially reduce the incidence and severity of clinical signs. Preliminary experiments have demonstrated some beneficial effects of anti-Ib12 antibody when given therapeutically; anti-Ib12 antibody treatment commencing at the time of onset of disease (1 wk after transfer) and continuing for a period of 6 d resulted in a reduction in the rate of disease progression, although the ultimate severity was not changed (Leonard, J. P., unpublished observation).
Inhibition of endogenous Ib12 by an anti-IL-12 antibody produced changes in the kinetics of disease transfer very similar to those seen after inhibition of integrin-mediated cell adhesion (15) . Interactions between lymphocytes and endothelial cells appear to play a major role in regulating the entry of antigen specific cells into the CNS (17, 18) . By use of PLPspecific T cell clones, the expression of the oe431 integrin (very late antigen 4 [VLA-4]) was found to be a prerequisite for the successful transfer of EAE (19) . In addition, antibodies directed against VLA-4 blocked both lymphocyte and monocyte binding to vessels on EAE brain slices (20) and delayed the onset of disease after transfer of MBP-specific T cell clones (15) . Similarly, antibodies against vascular cell adhesion molecule 1, the endothelial cell ligand for VLA-4, delayed the onset of disease after the transfer of MBP-specific T cell clones or MBP-stimulated LNC (15) . Interestingly, the continued administration of anti-VLA-4 antibody delayed the onset of clinical signs and reduced the severity of disease (15) in a manner similar to that seen by use of an antibody against murine I1.-12. In our studies, the slightly earlier onset of disease and rapid progression to complete hind limb paralysis after rmlb12 administration in vivo, as well as the delayed onset of disease after administration of an antibody to II.-12 in vivo, are consistent with modulation of integrin adhesion function as a potential component contributing to the effects of I1.-12 in this model.
The requirements for successful transfer of EAE via either antigen-stimulated primary LNC or antigen-specific CD4 + T cell lines or clones are complex and incompletely understood. The results of our experiments with an adoptive transfer model of EAE support a major role for Ib12 in regulating the T cell response to PLP and, consequently, the severity of transferred disease. More importantly, the data show that IL-12 is required in vivo for efficient effector function in this model. The ability of Ib12 to stimulate Thl T cells and its pivotal role in regulating effector function may have significant implications for the etiology of autoimmune diseases such as multiple sclerosis.
